Tempus to Present 10 AI-Driven Oncology Abstracts at ASCO25

Massive Bio Exhibiting at ASCO25 Massive Bio, a global leader in AI-powered clinical trial matching and oncology data solutions, is set to participate in the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held from May 30 to June 3 at McCormick Place in Chicago, Illinois. The company is showcasing its technology at Booth IH04 in the Innovation Hub, emphasizing its mission to expand access to clinical research through digital innovation and real-world data. Selin Kurnaz, Massive Bio's Co-founder and CEO, noted that the company strives to ensure that access to clinical trials does not depend on geography, income, or system navigation. "ASCO25 is more than a conference; it's a platform for forming meaningful partnerships and addressing shared challenges," Kurnaz stated. She will be participating in the PCC Drop-In Session on May 30, focusing on advancements in comprehensive genomic profiling, clinical trial matching, and patient-centered care. Çağatay Çulcuoğlu, Co-founder, CTO, and COO, emphasized the convergence of science, technology, and care delivery at ASCO. "We’re bringing advanced technology and a vision for a more connected and intelligent ecosystem where data informs better decisions, ensuring every patient has a fair chance to engage in research," he added. Scientific Contributions by Dr. Arturo Loaiza-Bonilla Dr. Arturo Loaiza-Bonilla, Massive Bio's Co-founder and Chief Medical Officer, is presenting two scientific talks at ASCO25. He is also a co-author of a recent New England Journal of Medicine (NEJM) article titled "Harnessing Moravec’s Paradox in Health Care: A New Era of Collaborative Intelligence." This article delves into the role of AI in enhancing research workflows and enabling patient-centric trial access. Loaiza-Bonilla highlighted the maturity of technology in meeting patients at the right time and offering them appropriate opportunities, regardless of the complexity of their diagnosis. "At ASCO25, we’re proud to share how real-world data, artificial intelligence, and clinical expertise are breaking longstanding barriers in oncology research," he explained. Booth Activities and Highlights At their booth, Massive Bio will demonstrate their patient-trial matching platform, which uses AI to connect cancer patients with suitable clinical trials, regardless of their location. Visitors can also learn about the company's real-world evidence solutions designed to inform clinical decisions and drive research. Meetings can be scheduled in advance at www.massivebio.com/asco25. About Massive Bio Founded by Selin Kurnaz, Arturo Loaiza-Bonilla, and Çağatay Çulcuoğlu, Massive Bio aims to transform the pharmaceutical value chain with AI-driven solutions. The company operates in 17 countries and employs over 100 people, collaborating with pharmaceutical companies, research organizations, and healthcare institutions worldwide. Massive Bio is a founding member of the CancerX public-private partnership and a participant in the Cancer Moonshot White House initiative. Recognized by the National Cancer Institute, the company is committed to enhancing the patient journey and optimizing clinical trials through data and technology. Tempus AI Announces Presentation of Ten Abstracts at ASCO25 In another significant announcement, Tempus AI, Inc., a technology leader in AI for precision medicine, revealed that ten abstracts have been accepted for presentation at the 2025 ASCO Annual Meeting. Tempus' Chief Medical Officer of Oncology, Ezra Cohen, MD, expressed pride in showcasing a diverse portfolio of studies. These presentations cover cutting-edge technologies such as tumor-naive and tumor-informed minimal residual disease (MRD) monitoring, whole genomic sequencing for hematologic malignancies, and multi-omic biomarker profiling. Cohen stated, "tempus is excited to share these advancements and collaborate with the oncology community to shape the future of precision medicine. Our technologies provide actionable insights to personalize treatment and improve patient outcomes." Research Highlights Key research presented by Tempus includes: Minimal Residual Disease (MRD) Monitoring: Both tumor-naive and tumor-informed approaches are discussed, offering detailed insights into detecting and managing residual cancer cells post-treatment. Whole Genomic Sequencing: Focus on hematologic malignancies, providing a comprehensive genetic map to guide treatment decisions. Multi-Omic Biomarker Profiling: Combining multiple types of biological data to identify biomarkers that can predict treatment responses and outcomes. These innovations are aimed at equipping clinicians and researchers with the tools needed to deliver personalized care and advance the field of oncology. About Tempus Tempus is a technology company dedicated to advancing precision medicine through AI applications in healthcare. The company boasts one of the world's largest libraries of multimodal data, making it accessible and useful for medical professionals. Tempus' AI solutions help physicians tailor treatments and contribute to the development of optimal therapeutics. Their goal is to benefit each patient by learning from past cases and continuously improving their data-driven tools. For more information, visit tempus.com. Forward-Looking Statements This press release includes forward-looking statements regarding Tempus and its industry, involving substantial risks and uncertainties. These statements, including those related to the quality of Tempus' research, customer retention, regulatory compliance, and financial performance, are based on current assumptions and expectations. Tempus encourages readers to review the "Risk Factors" section in its latest SEC filings for a detailed understanding of the risks and uncertainties that could impact the company's future. Industry Evaluation and Insights Industry insiders view Massive Bio and Tempus AI's participation in ASCO25 as pivotal steps towards democratizing access to advanced cancer treatments. The integration of AI and real-world data is seen as crucial in overcoming existing barriers in clinical trial enrollment and personalized treatment. These initiatives align with broader efforts to leverage technology for more effective and equitable healthcare practices, signaling a promising future in oncology research and patient care.